MRNS Marinus Pharmaceuticals, Inc.

1.51
0  -1%
Previous Close 1.53
Open 1.51
Price To book 1.40
Market Cap 32.53M
Shares 21,542,000
Volume 232,598
Short Ratio 2.75
Av. Daily Volume 1,707,060

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to commence in 1H 2017 with data due in 2H 2017.
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 trial to commence in 1H 2017 with data due in 2H 2017.
Ganaxolone
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 2 preliminary CDKL5 cohort data released January 23, 2017. Top-line data due mid-2017.
Ganaxolone
CDKL5 disorder

Latest News

  1. Ultragenyxs’ Seizure Drug Fails Study
  2. MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
  3. MARINUS PHARMACEUTICALS INC Financials
  4. Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference
  5. MARINUS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
  6. Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results
  7. Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model
  8. MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
  9. Marinus Appoints Michael R. Dougherty to its Board of Directors
  10. Marinus Releases Positive Preliminary Data from CDKL5 Study
  11. MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  12. Why This Seizure Drug Matters So Much for Marinus Pharma
  13. Marinus Anti-Seizure Drug Did Well in Early Trial
  14. Marinus Pharma stock surges 49% on positive mid-stage data for pediatric epilepsy drug
  15. Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder
  16. MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
  17. MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  18. Marinus Provides Business Outlook for 2017
  19. Marinus Provides Business Outlook for 2017
  20. Main Line biopharm firm gets a boost from the FDA